Intensity Therapeutics grants director 5,500 stock options

Intensity Therapeutics, Inc. reported that director Thomas I H Dubin was granted a stock option to acquire 5,500 shares of Common Stock at an exercise price of $4.90 per share.

Rhea-AI Filing Summary

Intensity Therapeutics, Inc. reported that director Thomas I H Dubin was granted a stock option to acquire 5,500 shares of Common Stock at an exercise price of $4.90 per share. The option expires on July 16, 2036 and will vest in four equal annual installments beginning July 16, 2026, subject to his continued service with the company. Following this grant, he directly holds options for 5,500 shares.

Insider Trade Summary

Grant/Award: 5,500 shares

Grant/Award 1 txn

Insider DUBIN THOMAS I H

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy Common Stock) F1	5,500	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy Common Stock) — 5,500 contracts (Direct)

Footnotes (1)

1. F1. This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on July 16, 2026.

Key Figures

Options Granted: 5,500 options Exercise Price: $4.90 per share Expiration Date: July 16, 2036 +3 more

6 metrics

Options Granted 5,500 options Stock option grant to director Thomas I H Dubin on July 16, 2026

Exercise Price $4.90 per share Conversion or exercise price of the granted stock option

Expiration Date July 16, 2036 Expiration of the director’s stock option grant

Underlying Shares 5,500 shares Common Stock underlying the granted stock option

Vesting Start Date July 16, 2026 First vesting date; four equal annual installments, subject to continued service

Post-Grant Holdings 5,500 options Total derivative securities held by the director after the grant

Key Terms

Stock Option, exercise price, expiration date, vesting

4 terms

Stock Option financial

"Stock Option (right to buy Common Stock)"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"conversion_or_exercise_price: "4.9000""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-07-16""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"This option will vest, subject to the individual's continued service"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did INTENSITY THERAPEUTICS (INTS) report for Thomas I H Dubin?

Intensity Therapeutics reported that director Thomas I H Dubin received a grant of 5,500 stock options to buy Common Stock at $4.90 per share, expiring July 16, 2036, as part of his director compensation.

How many INTENSITY THERAPEUTICS (INTS) shares are covered by the new option grant?

The reported option grant covers 5,500 shares of Intensity Therapeutics Common Stock. These shares are issuable upon exercise of the stock option, which was granted to director Thomas I H Dubin as disclosed in the insider transaction report.

What is the exercise price and term of the new INTENSITY THERAPEUTICS (INTS) stock option?

The stock option granted to the director has an exercise price of $4.90 per share and an expiration date of July 16, 2036. This defines the price he may pay and the last date on which he can exercise the option.

How do the INTENSITY THERAPEUTICS (INTS) options granted to the director vest?

The option granted to the director will vest in four equal annual installments, beginning on July 16, 2026. Vesting is explicitly conditioned on his continued service with Intensity Therapeutics for each annual installment date.

What is the director’s INTENSITY THERAPEUTICS (INTS) option position after this grant?

After the reported transaction, the director directly holds 5,500 stock options for Intensity Therapeutics Common Stock. This figure reflects his total option holdings reported in this insider transaction, following the new grant on July 16, 2026.

Is the INTENSITY THERAPEUTICS (INTS) option grant a market purchase or a compensation award?

The transaction is coded as a grant, award, or other acquisition of a derivative security, indicating a compensation-related stock option award to the director, not an open-market purchase of existing Intensity Therapeutics shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/20/2026 - 04:04 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DUBIN THOMAS I H

(Last) (First) (Middle)

C/O INTENSITY THERAPEUTICS, INC.

1 ENTERPRISE DRIVE, SUITE 430

(Street)

SHELTON CONNECTICUT 06484

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
INTENSITY THERAPEUTICS, INC. [ INTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy Common Stock)	$4.9	07/16/2026		A		5,500		07/16/2026(1)	07/16/2036	Common Stock	5,500	$0	5,500	D

Explanation of Responses:

1. This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on July 16, 2026.

Remarks:

	/s/ Kostantinos Skordalos, Attorney-in-fact	07/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)